LEIDEN, NETHERLANDS -- (MARKET WIRE) -- September 14, 2006 -- Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) announced today that it has started an evaluation program with Novartis AG. The program will apply Crucell's STAR™ technology for the selection of biopharmaceuticals production cell lines and to adapt such procedures to specific parental cell lines. The program will be performed with different monoclonal antibodies. Further details were not disclosed.
